Linical Co., Ltd. (2183)

Market cap
¥5.1B
P/E ratio
25.7x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
Period EndReturn on Assets (Million JPY)YoY (%)
Mar 31, 2026-15.6+410.16%
Mar 31, 2025-3-262.23%
Mar 31, 20241.9-68.93%
Mar 31, 20236.1+18.63%
Mar 31, 20225.1+39.34%
Mar 31, 20213.7+4.27%
Mar 31, 20203.5-30.50%
Mar 31, 20195.1-65.81%
Mar 31, 201814.8-21.31%
Mar 31, 201718.8-9.98%
Mar 31, 201620.9
AI Chat